AUTHENTICATED
`US. GOVERNMENT,
`INFORMATION,
`GPO,
`
`42500
`Federal Register/Vol. 87, No. 135/Friday, July 15, 2022 / Notices
`
`2022. In addition, any person who has
`not entered an appearanceas a party to
`the investigations may submit a written
`statementof information pertinent to
`the subject of the investigations,
`including statements of support or
`opposition to the petition, on or before
`November 15, 2022. On December1,
`2022, the Commission will make
`available to parties all information on
`which they have not had an opportunity
`to comment. Parties may submitfinal
`comments on this information on or
`before December 5, 2022, but such final
`comments must not contain new factual
`information and must otherwise comply
`with § 207.30 of the Commission’s rules.
`All written submissions must conform
`with the provisions of § 201.8 of the
`Commission’s rules; any submissions
`that contain BPI must also conform with
`the requirements of §§ 201.6, 207.3, and
`207.7 of the Commission’s rules. The
`Commission’s Handbook on Filing
`Procedures, available on the
`Commission’s website at https://
`www.usitc.gov/documents/handbook_
`on_filing_procedures.pdf, elaborates
`upon the Commission’s procedures with
`respectto filings.
`Additional written submissionsto the
`Commission, including requests
`pursuantto § 201.12 of the
`Commission’s rules, shall not be
`accepted unless good cause is shown for
`accepting such submissions, or unless
`the submission is pursuantto a specific
`request by a Commissioneror
`Commissionstaff.
`
`In accordance with §§ 201.16(c) and
`207.3 of the Commission’s rules, each
`documentfiled by a party to the
`investigations must be served onall
`other parties to the investigations (as
`identified by either the public or BPI
`service list), and a certificate of service
`mustbe timely filed. The Secretary will
`not accept a documentforfiling without
`a certificate of service.
`
`Authority: These investigations are
`being conducted under authority oftitle
`VII of the Tariff Act of 1930; this notice
`is published pursuantto § 207.21 of the
`Commission’s rules.
`
`Issued: July 11, 2022.
`Katherine Hiner,
`Acting Secretary to the Commission.
`[FR Doc. 2022-15101 Filed 7-14-22; 8:45 am]
`BILLING CODE 7020-02-P
`
`INTERNATIONAL TRADE
`COMMISSION
`
`[Investigation No. 337-TA-1266]
`
`Certain Wearable Electronic Devices
`With ECG Functionality and
`Components Thereof; Notice of
`Request for Submissions on the Public
`Interest
`
`AGENCY:U.S. International Trade
`Commission.
`ACTION: Notice.
`
`SUMMARY:Notice is hereby given that on
`June 27, 2022, the presiding
`administrative law judge (“ALJ”) issued
`an Initial Determination on Violation of
`Section 337. The ALJ also issued a
`Recommended Determination on
`remedy and bonding should a violation
`be foundin the above-captioned
`investigation. The Commissionis
`soliciting submissions on public interest
`issues raised by the recommendedrelief
`should the Commission find a violation.
`This notice is soliciting comments from
`the public only.
`FOR FURTHER INFORMATION CONTACT:
`Panyin A. Hughes, Office of the General
`Counsel, U.S. International Trade
`Commission, 500 E Street SW,
`Washington, DC 20436, telephone (202)
`205-3042. Copies of non-confidential
`documents filed in connection with this
`investigation may be viewed on the
`Commission’s electronic docket (EDIS)
`at hitps://edis.usitc.gov. For help
`accessing EDIS, please email
`EDIS3Help@usitc.gov. General
`information concerning the Commission
`may also be obtained by accessingits
`internet server at https://www.usitc.gov.
`Hearing-impaired personsare advised
`that information on this matter can be
`obtained by contacting the
`Commission’s TDD terminal on (202)
`205-1810.
`SUPPLEMENTARYINFORMATION: Section
`337 of the Tariff Act of 1930 provides
`that, if the Commission finds a
`violation, it shall excludethearticles
`concerned from the United States:
`
`unless, after considering the effect of such
`exclusion upon the public health and
`welfare, competitive conditions in the United
`States economy, the production of like or
`directly competitive articles in the United
`States, and United States consumers, it finds
`that such articles should not be excluded
`from entry.
`19 U.S.C. 1337(d)(1). A similar
`provision applies to cease and desist
`orders, 19 U.S.C. 1337(f)(1).
`The Commissionis soliciting
`submissions on public interest issues
`raised by the recommendedrelief
`should the Commission find a violation,
`
`specifically: a limited exclusion order
`directed to certain wearable electronic
`devices with ECG functionality and
`components thereof imported, sold for
`importation, and/orsold after
`importation by respondent Apple Inc. of
`Cupertino, California (“Apple”); and
`cease and desist orders directed to
`Apple. Parties are to file public interest
`submissions pursuant to 19 CFR
`210.50(a)(4).
`The Commission is interested in
`further developmentof the record on
`the public interest in this investigation.
`Accordingly, membersof the public are
`invited to file submissions of no more
`than five (5) pages, inclusive of
`attachments, concerning the public
`interest in light of the ALJ’s
`Recommended Determination on
`Remedy and Bondingissuedin this
`investigation on June 27, 2022.
`Comments should address whether
`issuance of the recommended remedial
`orders in this investigation, should the
`Commission find a violation, would
`affect the public health and welfare in
`the United States, competitive
`conditions in the United States
`economy, the production oflike or
`directly competitive articles in the
`United States, or United States
`consumers.
`In particular, the Commission is
`interested in commentsthat:
`(i) explain how thearticles potentially
`subject to the recommendedremedial
`orders are used in the United States;
`(ii) identify any public health,safety,
`or welfare concernsin the United States
`Telating to the recommendedorders;
`(iii) identify like or directly
`competitive articles that complainant,
`its licensees, or third parties make in the
`United States which could replace the
`subjectarticles if they were to be
`excluded;
`(iv) indicate whether complainant,
`complainant’s licensees, and/or third-
`party suppliers have the capacity to
`replace the volumeofarticles
`potentially subject to the recommended
`orders within a commercially
`reasonable time; and
`(v) explain how the recommended
`orders would impact consumersin the
`United States.
`Written submissions mustbefiled no
`later than by close of business on July
`27, 2022.
`Personsfiling written submissions
`mustfile the original document
`electronically on or before the deadlines
`stated above. The Commission’s paper
`filing requirements in 19 CFR 210.4(f)
`are currently waived. 85 FR 15798 (Mar.
`19, 2020). Submissions should refer to
`the investigation number(‘‘Inv. No.
`337-TA-1266”) in a prominentplace on
`
`

`

`42501
`Federal Register/Vol. 87, No. 135/Friday, July 15, 2022 / Notices
`
`Conirolled substance
`
`Schedule Psilocybin ...........25
`
`DEPARTMENTOF JUSTICE
`
`Drug Enforcement Administration
`
`[Docket No. DEA-1033]
`
`Importer of Controlled Substances
`Application: Xcelience
`
`AGENCY: Drug Enforcement
`Administration, Justice.
`ACTION: Notice of application.
`
`SUMMARY:Xcelience has applied to be
`registered as an importerof basic
`class(es) of controlled substance(s).
`Refer to SUPPLEMENTARY INFORMATION
`listed below for further drug
`information.
`
`The company plans to import drug
`code 7437 (Psilocybin) as finished
`dosagefor clinical trials research, and
`analytical purposes. No otheractivity
`for this drug codeis authorized for this
`registration.
`Approval of permit applications will
`occur only whentheregistrant’s
`businessactivity is consistent with what
`is authorized under 21 U.S.C. 952(a)(2).
`Authorization will not extendto the
`import of Food and Drug
`Administration-approved or non-
`approved finished dosage forms for
`commercialsale.
`
`the cover page and/orthefirst page. (See
`Handbookfor Electronic Filing
`Procedures, https://www.usitc.gov/
`documents/handbook_on_filing_
`procedures.pdf.). Persons with
`questions regardingfiling should
`contact the Secretary (202-205-2000).
`Any person desiring to submit a
`documentto the Commission in
`confidence must request confidential
`treatment by marking each document
`with a header indicating that the
`document contains confidential
`information. This marking will be
`deemedto satisfy the request procedure
`set forth in Rules 201.6(b) and
`210.5(e)(2) (19 CFR 201.6(b) &
`210.5(e)(2)). Documents for which
`DATES: Registered bulk manufacturers of
`confidential treatment by the
`the affected basic class{es), and
`Commission is properly sought will be
`applicants therefore, may submit
`treated accordingly. Any non-party
`electronic comments onor objectionsto
`wishing to submit comments containing
`the issuanceof the proposedregistration
`confidential information must serve
`on or before August 15, 2022. Such
`those comments on theparties to the
`persons mayalsofile a written request
`investigation pursuantto the applicable
`for a hearing on the application on or
`Administrative Protective Order. A
`before August 15, 2022.
`redacted non-confidential version of the
`ADDRESSES: The Drug Enforcement
`document mustalso be filed
`Administration requires that all
`simultaneously with any confidential
`comments be submitted electronically
`filing and must be served in accordance
`through the Federal eRulemakingPortal,
`with Commission Rule 210.4(£)(7)(ii)(A)
`which providesthe ability to type short
`(19 CFR 210.4(f)(7)(Gi)(A)). All
`comments directly into the comment
`information, including confidential
`field on the web pageorattacha file for
`business information and documents for
`lengthier comments. Please go to
`which confidential treatment is properly
`https://www.regulations.gov and follow
`sought, submitted to the Commission for
`the online instructionsat thatsite for
`purposesofthis investigation may be
`submitting comments. Upon submission
`disclosed to and used:(i) by the
`of your comment,you will receive a
`Commission, its employees and Offices,
`Comment Tracking Number. Please be
`and contract personnel(a) for
`aware that submitted commentsare not
`developing or maintaining the records
`instantaneously available for public
`of this or a related proceeding,or (b) in
`view on https://www.regulations.gov.If
`internal investigations, audits, reviews,
`you have received a Comment Tracking
`and evaluationsrelating to the
`Number, your commenthas been
`programs, personnel, and operations of
`successfully submitted and there is no
`the Commission including under5
`need to resubmit the same comment. All
`DATES: Registered bulk manufacturers of
`U.S.G. Appendix3; or (ii) by U.S.
`the affected basic class(es), and
`requests for a hearing must be sentto:
`government employees and contract
`applicants therefore, may submit
`(1) Drug Enforcement Administration,
`personnel, solely for cybersecurity
`electronic comments on or objections to
`Attn: Hearing Clerk/OAL)J, 8701
`purposes. All contract personnel will
`the issuance of the proposedregistration
`Morrissette Drive, Springfield, Virginia
`sign appropriate nondisclosure
`on or before August 15, 2022. Such
`22152; and (2) Drug Enforcement
`agreements. All nonconfidential written
`persons mayalsofile a written request
`Administration, Attn: DEA Federal
`submissions will be available for public
`for a hearing on the application on or
`Register Representative/DPW,8701
`inspection on EDIS.
`before August 15, 2022.
`Morrissette Drive, Springfield, Virginia
`This action is taken under the
`22152. All requests for a hearing should
`ADDRESSES: The Drug Enforcement
`authority of section 337 of the Tariff Act
`also be sent to: Drug Enforcement
`Administration requiresthat all
`of 1930, as amended(19 U.S.C. 1337),
`Administration, Attn: Administrator,
`comments be submitted electronically
`andin Part 210 of the Commission’s
`8701 Morrissette Drive, Springfield,
`through the Federal eRulemakingPortal,
`Rules of Practice and Procedure (19 CFR
`Virginia 22152.
`which providesthe ability to type short
`SUPPLEMENTARYINFORMATION: In
`part 210).
`commentsdirectly into the comment
`field on the web pageor attachafile for
`accordance with 21 CFR 1301.34(a), this
`By order of the Commission.
`lengthier comments. Please go to
`is notice that on May 17, 2022,
`Issued: July 11, 2022.
`hittps://www.regulations.gov and follow
`Xcelience, 4901 West Grace Street,
`Katherine Hiner,
`the online instructionsat that site for
`Tampa, Florida 33607-3807, applied to
`Acting Secretary to the Commission.
`submitting comments. Upon submission
`be registered as an importerof the
`[FR Doc. 2022-15102 Filed 7-14-22; 8:45 am]
`of your comment, you will receive a
`followingbasic class(es) of controlled
`BILLING CODE 7020-02-P
`CommentTracking Number. Please be
`substance(s):
`
`Kristi O’Malley,
`Assistant Administrator.
`[FR Doc. 2022-15107 Filed 7-14-22; 8:45 am]
`BILLING CODE P
`
`
`DEPARTMENTOF JUSTICE
`
`Drug Enforcement Administration
`[Docket No. DEA-1034]
`
`Importer of Controlled Substances
`Application: AndersonBrecon, Inc.
`DBA PCI PharmaServices
`
`AGENCY: Drug Enforcement
`Administration, Justice.
`ACTION: Notice of application.
`
`SUMMARY: AndersonBrecon, Inc. DBA
`PCI PharmaServiceshas applied to be
`registered as an importerof basic
`class(es) of controlled substance(s).
`Refer to SUPPLEMENTARY INFORMATION
`listed below for further drug
`information.
`
`